Gilead plans to quickly advance once-yearly PrEP for HIV
16h
MedPage Today on MSNOnce-Yearly Lenacapavir PrEP a Safe, Promising Alternative to Twice-Yearly DosingA once-yearly intramuscular lenacapavir (Sunlenca) injection was safe and well-tolerated and had higher median levels of ...
Gilead has reported results for a once-yearly intramuscular injection that show blood concentrations of lenacapavir exceeded ...
A clinical trial suggests Lenacapavir, a yearly injection, could revolutionise HIV prevention by offering long-term ...
After Gilead Sciences' lenacapavir made waves with stellar clinical results as a twice-yearly HIV prevention candidate, the ...
Promising results from an early-stage trial suggest that lenacapavir injections might offer long-lasting protection.
1d
Queerty on MSNA once-a-year PrEP injection? The results of the first clinical trial look promisingPharma giant Gilead Sciences has revealed the results of its first, Phase 1 trial into a once-a-year PrEP injection. The ...
2d
News-Medical.Net on MSNGilead’s capsid revolution meets our capsid solutions: Sino Biological – Engineering the tools to outsmart HIVGilead Sciences announced a significant milestone: the U.S. FDA accepted their New Drug Applications (NDAs) for lenacapavir ...
The drug, which works by blocking HIV from entering and multiplying in human cells, remained in the body for at least 56 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results